Archivos De La Sociedad Espanola De Oftalmologia最新文献

{"title":"Correlación del diámetro pupilar en la incidencia de complicaciones transquirúrgicas en los pacientes con seudoexfoliación sometidos a cirugía de catarata por facoemulsificación","authors":"A.S. León Valle,&nbsp;C. Palacio Pastrana,&nbsp;W. Cedillo Suárez,&nbsp;L.E. Salas Medina","doi":"10.1016/j.oftal.2026.502501","DOIUrl":"10.1016/j.oftal.2026.502501","url":null,"abstract":"<div><h3>Background and objective</h3><div>Study the correlation between pupillary diameter and intraoperative complications in patients with pseudoexfoliation undergoing phacoemulsification.</div></div><div><h3>Material and methods</h3><div>Prospective, observational, and descriptive study. Data were collected from May 2024 to May 2025.</div></div><div><h3>Results</h3><div>Preoperative pupillary diameter &lt;<!--> <!-->5.5<!--> <!-->mm post dilation was significantly associated with the development of intraoperative complications (<em>P</em>=.002). Among patients with complications, the median pupil dilation was 4.99<!--> <!-->mm, whereas in those without complications the median was 5.94<!--> <!-->mm. Most complications occurred during the phacoemulsification phase (6; 66.7%), followed by capsulorhexis (2; 22.2%). Additionally, the presence of zonular weakness was significantly associated with the development of complications (<em>P</em>&lt;.001).</div></div><div><h3>Conclusions</h3><div>Preoperative identification of a pupil diameter &lt;<!--> <!-->5.5<!--> <!-->mm post dilation may alert the surgeon to potential intraoperative findings such as zonular weakness and iris instability, which may lead to better surgical planning.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502501"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio retrospectivo sobre la predictibilidad de la fórmula Barrett TK Universal II con el IOLMaster 700 en un hospital público universitario en 193 cirugías","authors":"P. Puy,&nbsp;D. Carrascosa,&nbsp;C. Fernández,&nbsp;N. Toledano","doi":"10.1016/j.oftal.2026.502500","DOIUrl":"10.1016/j.oftal.2026.502500","url":null,"abstract":"<div><h3>Background and objective</h3><div>The refractive outcome is one of the factors that determine the success of cataract surgery. This result depends largely on the calculation of the intraocular lens. Technological advances have enhanced the accuracy of this calculation using high-precision biometers and new biometric formulas. The aim of this study is to evaluate the refractive predictive accuracy of the Barrett TK Universal II formula using IOLMaster 700 technology under real-world clinical conditions in a public university hospital setting.</div></div><div><h3>Materials and methods</h3><div>This is a retrospective study performed between October 2021 and February 2023. Biometric variables were recorded using the IOLMaster 700, applying the Barrett TK Universal II formula for the calculation of intraocular lens power. The mean absolute (MAE) and relative (ME) prediction error at three months post-surgery were analyzed, as well as the influence of preoperative variables on the achieved refractive outcome.</div></div><div><h3>Results</h3><div>193 patients have been studied, with a mean age of 73.58<!--> <!-->±<!--> <!-->9.09 years. The ME was -0.09<!--> <!-->±<!--> <!-->0.5<!--> <!-->diopters (D), and the MAE was 0.39<!--> <!-->±<!--> <!-->0.32D. 67.88% of the patients ended up within<!--> <!-->±<!--> <!-->0.5<!--> <!-->D of the target refraction, and 95.85% within<!--> <!-->±<!--> <!-->1D. No significant correlation was found between the MAE and any of the studied variables.</div></div><div><h3>Conclusions</h3><div>The findings support the importance of having precise technology for performing biometrics such as the IOLMaster 700 and the use of last-generation formulas such as the Barrett TK Universal II.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502500"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eficacia y seguridad de Ziv-Aflibercept intravítreo para el tratamiento del edema macular: una revisión sistemática y metaanálisis","authors":"F. Munayco-Guillén ,&nbsp;M. García-Roa ,&nbsp;M. Vázquez-Membrillo ,&nbsp;R. Pichardo-Rodríguez","doi":"10.1016/j.oftal.2026.502465","DOIUrl":"10.1016/j.oftal.2026.502465","url":null,"abstract":"<div><h3>Background and objective</h3><div>Intravitreal Ziv-Aflibercept (ZA-IV) is a recombinant fusion protein used to treat macular diseases. Several studies have demonstrated its efficacy and safety. The objective was to evaluate the efficacy and safety of ZA-IV in the treatment of diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO).</div></div><div><h3>Materials and methods</h3><div>Systematic review with meta-analysis (PROSPERO: CRD42024542788), with searches in PubMed, EMBASE, and Web of Science up to April 2024. Observational studies and randomized controlled trials (RCTs) were included. Efficacy was determined by best-corrected visual acuity (BCVA) and central macular thickness (CMT). Safety was assessed based on the reports in the studies. Risk of bias was assessed using the Robins-I and Cochrane RoB 2.0 tools.</div></div><div><h3>Results</h3><div>Of 503 studies, 8 observational studies and 5 RCTs were included. In DME, RCTs showed a reduction in CMT (−105<!--> <!-->μm; 95%<!--> <!-->CI: −129.8 to −80.3; I²: 0%) and in BCVA a LogMAR reduction (−0.29; 95%<!--> <!-->CI: −0.36 to −0.21; I²: 0%). Observational studies in DME showed a reduction in CMT (−108<!--> <!-->μm; 95%<!--> <!-->CI: −133 to −83.1; I²: 34%) and in BCVA a LogMAR reduction (−0.2; 95%<!--> <!-->CI: −0.26 a −0.14; I²: 0%). In RVO, RCTs showed a reduction in CMT (−230<!--> <!-->μm; 95%<!--> <!-->CI: −367 to −94; I²: 46%). Observational studies in EMSOV showed a reduction in GMC (−160<!--> <!-->μm; 95%<!--> <!-->CI: −257 to −64; I²: 74%) and in BCVA (best corrected visual acuity) a reduction in LogMAR (−0.2; 95%<!--> <!-->CI: −0.26 to −0.14; I²: 50%). No serious ocular or systemic adverse effects were reported.</div></div><div><h3>Conclusion</h3><div>ZA-IV demonstrated efficacy and is potentially safe for the treatment of EMD and EMSOV.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502465"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lentes fáquicas para el manejo de la presbicia: una tecnología adelantada a su evidencia","authors":"J.H. González-Lugo ,&nbsp;J.L. Alió del Barrio","doi":"10.1016/j.oftal.2026.502487","DOIUrl":"10.1016/j.oftal.2026.502487","url":null,"abstract":"","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502487"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tocilizumab y azatioprina en el manejo del edema macular refractario asociado a Behçet: experiencia clínica","authors":"F.J. Barroso Pérez ,&nbsp;P. Bañeros Rojas ,&nbsp;C. De la Cruz Tapiador","doi":"10.1016/j.oftal.2026.502508","DOIUrl":"10.1016/j.oftal.2026.502508","url":null,"abstract":"<div><div>A 32-year-old man of Maghrebi origin consulted for visual loss in both eyes (OU) with recurrent oral ulcers and erythematous lesions. The examination revealed panuveitis in the right eye, posterior uveitis in the left eye and cystic macular edema (CME) in OU. Along with mucocutaneous lesions and the presence of HLA B51 positive suggested a diagnosis of Behçet's disease. He was initially treated with pulses of Methylprednisolone followed by oral Prednisone and Azathioprine (AZA). Given the insufficient control, Adalimumab (ADA) was added. Due to the lack of visual improvement and worsening of the CME, it was decided to switch from ADA to Tocilizumab (TCZ) at a dose of 8<!--> <!-->mg/kg/month. After three years of follow-up, he remained stable at the systemic and ocular levels with AZA and TCZ, and oral corticosteroids were discontinued.</div><div>In cases where signs of ocular activity persist, a change in biological therapeutic target should be considered, with Tocilizumab being a beneficial option.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502508"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coriorretinopatía serosa central infantil: una causa infrecuente de desprendimiento neurosensorial macular","authors":"A.J. Corona Castro,&nbsp;M. Nieves Moreno,&nbsp;L. Domínguez García","doi":"10.1016/j.oftal.2026.502505","DOIUrl":"10.1016/j.oftal.2026.502505","url":null,"abstract":"<div><div>Central Serous Chorioretinopathy (CSC) is a pachychoroidopathy characterized by the accumulation of subretinal fluid due to alterations in the retinal pigment epithelium, affecting mainly to 30-50 years old men and being an extremely infrequent pathology in the pediatric age.</div><div>In this article we present the case of a 7-year-old patient with recent personal record of trip to Mauricio Islands who attends to the Emergency Room with serious loss of vision in an insidious way during the last week. A complete ophthalmologic examination was performed along with imaging tests (ocular ultrasound, OCTm, and optomap) revealing a large neurosensory retinal detachment (NSD) in the macular area associated with underlying choroidal thickening. Systemic workup, including a head CT, 18-FDG PET-CT, and serological marker analysis, was normal. The NSD resolved completely within 6 weeks with topical anti-inflammatory treatment.</div><div>Despite the sudden beginning of the clinical case and the wide variety of possible diagnosis, the self-limited and self-solving characteristics of the process, drives us to the diagnostic possibility of Central Serous Chorioretinopathy.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502505"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melatonina y glaucoma: conocimientos actuales y perspectivas clínicas","authors":"A. Martucci ,&nbsp;R. Rosa ,&nbsp;F. Aiello,&nbsp;R. Mancino,&nbsp;M. Cesareo ,&nbsp;C. Nucci","doi":"10.1016/j.oftal.2026.502549","DOIUrl":"10.1016/j.oftal.2026.502549","url":null,"abstract":"<div><div>This review aims to synthesize current evidence on the role of melatonin in glaucoma pathophysiology, its relationship with sleep disturbances and circadian dysregulation, and its potential as a therapeutic agent beyond intraocular pressure (IOP) control. Glaucoma is a chronic neurodegenerative optic neuropathy characterized by progressive retinal ganglion cells loss. While IOP remains the primary modifiable risk factor, disease progression often persists despite adequate pressure control, highlighting the need for adjunctive neuroprotective strategies. Sleep disturbances are highly prevalent in glaucoma and may reflect underlying circadian dysfunction.</div><div>This review integrates findings from clinical, experimental, and translational studies, including observational cohorts, meta-analyses, and mechanistic investigations of melatonin signaling, receptor distribution, and therapeutic modulation.</div><div>Melatonin secretion is significantly reduced in glaucoma, particularly in advanced stages, as demonstrated by urinary 6-sulfatoxymelatonin levels. Melatonin receptors 1 and 2 are expressed in multiple ocular tissues, including retinal ganglion cells, photoreceptors, and the ciliary body, mediating circadian regulation, antioxidant defense, and IOP modulation. Melatonin deficiency contributes to impaired intrinsically photosensitive retinal ganglion cells function, disrupted circadian entrainment, and neurodegeneration. Exogenous melatonin and analogues (e.g., 5-MCA-NAT, agomelatine) show promising IOP-lowering and neuroprotective effects in preclinical and early clinical studies. Novel delivery systems enhance ocular bioavailability and therapeutic efficacy.</div><div>Melatonin plays a multifaceted role in glaucoma, influencing circadian rhythms, sleep quality, IOP regulation, and retinal neuroprotection. Its therapeutic potential warrants further investigation through controlled trials and optimized delivery strategies. Addressing circadian dysregulation may offer a novel avenue for comprehensive glaucoma management. Therefore, a structured narrative search was conducted in PubMed using the keywords “glaucoma” AND “melatonin”, and findings were synthesized qualitatively due to methodological heterogeneity across clinical and preclinical studies.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502549"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redes sociales en oftalmología: de la oportunidad educativa a la responsabilidad profesional","authors":"J. Lacorzana","doi":"10.1016/j.oftal.2026.502478","DOIUrl":"10.1016/j.oftal.2026.502478","url":null,"abstract":"","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502478"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consideraciones metodológicas sobre la caracterización biométrica en una cohorte de pacientes con cataratas","authors":"F.J. Castro Alonso ,&nbsp;M. Jiménez García ,&nbsp;M. Puzo Bayod","doi":"10.1016/j.oftal.2026.502477","DOIUrl":"10.1016/j.oftal.2026.502477","url":null,"abstract":"","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 6","pages":"Article 502477"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148060172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Encuesta poblacional sobre salud visual en España","authors":"B. Benito-Pascual ,&nbsp;C. Fernández-Pérez ,&nbsp;A. Medina ,&nbsp;D. Rojo ,&nbsp;P. Arriola-Villalobos","doi":"10.1016/j.oftal.2026.502467","DOIUrl":"10.1016/j.oftal.2026.502467","url":null,"abstract":"<div><h3>Background and objective</h3><div>Conducting a national visual health survey and comparing results after 5 years.</div></div><div><h3>Materials and methods</h3><div>Cross-sectional study using a computer-assisted telephone interview with a representative sample of Spaniards over 18 years of age (except Ceuta and Melilla). The survey was designed by ophthalmologists, the selection of the sample and the conduct of the interviews (April 2017 and May 2023) was carried out through the company Metroscopia and the analysis of the anonymous data was carried out by researchers. Demographic data, knowledge about glaucoma, use of glasses, perceived visual quality, ophthalmological pathology and ocular treatments were collected.</div></div><div><h3>Results</h3><div>1209 and 600 people were interviewed in 2017 and 2023, respectively. The level of glaucoma awareness went from 80 to 87%. The perceived visual quality was reduced (8.2<!--> <!-->±<!--> <!-->1.6 to 6.9<!--> <!-->±<!--> <!-->1.8) and the frequency of access to the ophthalmologist. The prevalence of glasses use increased (50 to 62%), dry eye (13 to 28%), cataract (9.7 to 12.4%), glaucoma (1.9 to 4.6%), age-related macular degeneration (7 to 11.3%), and diabetic retinopathy (1.2 to 1.7%). The use of artificial tears and glaucoma drops also increased (16.9 to 32.9% and 1.6 to 6%, respectively).</div></div><div><h3>Conclusions</h3><div>The study shows that there has been an increase in self-reporting of eye diseases in recent years in Spain. These types of population surveys can serve to encourage the development of visual health programs aimed at the needs of our country.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 5","pages":"Article 502467"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147755723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}